JP2013511975A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511975A5
JP2013511975A5 JP2012540503A JP2012540503A JP2013511975A5 JP 2013511975 A5 JP2013511975 A5 JP 2013511975A5 JP 2012540503 A JP2012540503 A JP 2012540503A JP 2012540503 A JP2012540503 A JP 2012540503A JP 2013511975 A5 JP2013511975 A5 JP 2013511975A5
Authority
JP
Japan
Prior art keywords
cancer
disease virus
newcastle disease
virus clone
clone according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012540503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511975A (ja
JP5807788B2 (ja
Filing date
Publication date
Priority claimed from EP09075536A external-priority patent/EP2327764B1/en
Application filed filed Critical
Publication of JP2013511975A publication Critical patent/JP2013511975A/ja
Publication of JP2013511975A5 publication Critical patent/JP2013511975A5/ja
Application granted granted Critical
Publication of JP5807788B2 publication Critical patent/JP5807788B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012540503A 2009-11-30 2010-08-13 ニューカッスル病ウイルスの新規クローン、その作製及び癌治療への応用 Expired - Fee Related JP5807788B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28315409P 2009-11-30 2009-11-30
EP09075536.4 2009-11-30
EP09075536A EP2327764B1 (en) 2009-11-30 2009-11-30 New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
US61/283,154 2009-11-30
PCT/IB2010/002227 WO2011064630A1 (en) 2009-11-30 2010-08-13 New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Publications (3)

Publication Number Publication Date
JP2013511975A JP2013511975A (ja) 2013-04-11
JP2013511975A5 true JP2013511975A5 (enExample) 2013-10-03
JP5807788B2 JP5807788B2 (ja) 2015-11-10

Family

ID=41581942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540503A Expired - Fee Related JP5807788B2 (ja) 2009-11-30 2010-08-13 ニューカッスル病ウイルスの新規クローン、その作製及び癌治療への応用

Country Status (11)

Country Link
US (2) US8377450B2 (enExample)
EP (2) EP2327764B1 (enExample)
JP (1) JP5807788B2 (enExample)
KR (1) KR20120106741A (enExample)
CN (1) CN102803477B (enExample)
AT (1) ATE539148T1 (enExample)
CA (1) CA2782189C (enExample)
DK (1) DK2327764T3 (enExample)
ES (1) ES2380289T3 (enExample)
IL (1) IL207623A (enExample)
WO (1) WO2011064630A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2327764B1 (en) * 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
KR101636683B1 (ko) * 2013-08-28 2016-07-07 주식회사 바이오포아 내열성이 향상된 뉴캣슬병 바이러스 bp acndm
KR101653401B1 (ko) * 2013-08-28 2016-09-12 주식회사 바이오포아 내열성이 향상된 뉴캣슬병 바이러스 bp acnd
JP6731405B2 (ja) * 2014-11-07 2020-07-29 ケース ウエスタン リザーブ ユニバーシティ ウイルス粒子を用いた癌免疫療法
RU2644676C1 (ru) * 2016-10-18 2018-02-13 Общество с ограниченной ответственностью "Витагор" (ООО "ВИТАГОР") Штамм вируса болезни Ньюкасла NDVH-2 для изучения возможности разработки на его основе вирусного онколитического препарата
KR101964610B1 (ko) * 2017-03-13 2019-04-03 대한민국 신규한 종양용해성 바이러스 및 이의 용도
EP3552608A1 (en) * 2018-04-09 2019-10-16 Rapo Yerape B.H. Ltd Increased activity of oncoloytic newcastle disease virus
EP3844268A1 (en) * 2018-08-31 2021-07-07 Thaller, Arno Novel recombinant newcastle disease virus
CN113913553B (zh) * 2021-10-15 2024-08-27 广西壮族自治区兽医研究所 基因ⅻ型新城疫病毒荧光定量rt-pcr检测试剂盒及其引物对

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197846B (en) 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
HU197517B (en) 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
US5215745A (en) * 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
HU203983B (en) 1988-12-05 1991-11-28 Mta Allatorvostudomanyi Kutato Process for producing living vaccine against fowlpox
WO1993018790A1 (en) 1992-03-24 1993-09-30 Csatary Laszlo K Vaccine containing live virus for therapy of viral diseases and malignancies
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
FR2701580B1 (fr) 1993-02-10 1995-03-24 Bull Sa Procédé d'administration d'applications avec des protocoles standards.
PT1486211E (pt) 1993-04-30 2009-02-02 Wellstat Biologics Corp Composições para tratamento do cancro utilizando vírus
JPH08116976A (ja) 1994-10-20 1996-05-14 Chemo Sero Therapeut Res Inst 免疫用核酸調製物およびこれを用いた免疫方法
DE69632235T2 (de) 1995-10-18 2004-08-26 Akzo Nobel N.V. Newcastle-Krankheitsvirus-Kombinationsimpfstoff
FR2750866B1 (fr) * 1996-06-27 1998-11-27 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
NZ518945A (en) 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
AU4246900A (en) 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
AU4971500A (en) 1999-05-05 2000-11-21 University Of Maryland Production of novel newcastle disease virus strains from cdnas and improved liveattenuated newcastle disease vaccines
WO2000077218A1 (en) 1999-06-10 2000-12-21 Agricultural Research Council Vaccine for newcastle disease virus
CA2414396A1 (en) 2000-06-26 2002-01-03 The United States Of America, As Represented By The Secretary Of Agricul Ture Production of vaccines using transgenic plants
WO2002000233A2 (en) 2000-06-26 2002-01-03 Wellstat Biologics Corporation Purging of cells using viruses
MXPA03003700A (es) 2000-11-02 2004-05-04 Akzo Nobel Nv Mutante de nucleoproteina recombinante de virus de enfermedad de newcastle en la forma de una vacuna marcadora.
IL145397A0 (en) 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
WO2005113013A2 (en) 2004-05-20 2005-12-01 Theravir Management L.P. Compositions of ndv and methods of use thereof for treatment of cancer
RU2314830C2 (ru) 2002-06-21 2008-01-20 Веллстат Байолоджикс Корпорейшн Введение терапевтических вирусов
JP2005536538A (ja) * 2002-08-23 2005-12-02 シェーリング コーポレイション 薬学的組成物
EP1578451A4 (en) 2002-11-05 2007-01-24 Wellstat Biologics Corp TREATMENT OF CARCINOID TUMORS WITH THERAPEUTIC VIRUSES
NZ543058A (en) 2003-03-24 2008-04-30 Wellstat Biologics Corp Newcastle disease virus administration
NZ543056A (en) 2003-03-24 2008-04-30 Wellstat Biologics Corp Newcastle disease virus comprising a plurality of doses for treating a mammalian subject having a tumour
US20060018836A1 (en) 2003-11-25 2006-01-26 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain having a p53 independent oncolytic effect
US20060018884A1 (en) * 2003-11-25 2006-01-26 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
NZ550430A (en) 2004-04-27 2009-06-26 Wellstat Biologics Corp Cancer treatment using viruses and camptothecins
NZ581958A (en) 2004-11-12 2011-01-28 Bayer Schering Pharma Ag Recombinant newcastle disease virus comprising a transgene encoding a prodrug-converting enzyme or protease for use in the treatment of cancer
MX2007015407A (es) 2005-07-14 2008-02-19 Wellstat Biologics Corp Tratamiento del cancer utilizando virus, fluoropirimidinas y camptotecinas.
CN1772886A (zh) 2005-09-02 2006-05-17 中国农业科学院哈尔滨兽医研究所 表达传染性法氏囊病毒VP2基因的重组新城疫LaSota弱毒疫苗株
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
KR100801180B1 (ko) 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
EP2091972B1 (en) 2006-11-27 2016-01-13 Schirrmacher, Dr., Volker Multi-modal cancer therapy using viral hitch-hiking
WO2008140621A2 (en) * 2006-12-21 2008-11-20 Mount Sinai School Of Medicine Of New York University Transgenic oncolytic viruses and uses thereof
CN101205544B (zh) * 2007-08-07 2010-12-08 中国人民解放军第四军医大学 肿瘤靶向性重组新城疫病毒及其构建方法
EP2327764B1 (en) * 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Similar Documents

Publication Publication Date Title
JP2013511975A5 (enExample)
AU2014204386B2 (en) Method for treating tumor by using recombinant interferon with changed spatial configuration
JP7239910B2 (ja) 治療剤、ならびに腫瘍および/またはがんの治療のための薬物のためのその使用
JP2015517511A5 (enExample)
EP4186519A1 (en) Interferon-based cancer treatment method and pharmaceutical composition
JP2010525811A5 (enExample)
EP3064215A1 (en) Method for treatment of demyelinating central nervous system disease
Jiang et al. Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors
JP2016501208A (ja) ボラセルチブとの併用療法
WO2017177908A1 (zh) Pd-l1和pd-l2重组蛋白及其用途
Indrová et al. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I− tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines
JP2017533192A (ja) ペグ化インターフェロンのための投薬計画
Huang et al. Safety of lienal polypeptide injection combined with chemotherapy in treating patients with advanced cancer
CN115804853A (zh) 包含rna分子的组合物及其在制备瘤内注射剂中的用途
EP4282426A1 (en) Method and pharmaceutical combination for preventing cancer recurrence
EP4282427A1 (en) Interferon-based cancer treatment method, and pharmaceutical combination
JP7412576B2 (ja) 腎がんの相乗的治療におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の適用
RU2379055C1 (ru) Способ лечения онкологических заболеваний
CN112843092A (zh) 免疫细胞在治疗疾病中的应用及其制备方法
JP2022522914A (ja) 医学的使用
Yang et al. Increased Anti-tumor Effect by a Combination of HSV Thymidine Kinase Suicide Gene Therapy and Interferon-γ/GM-CSF Cytokine Gene Therapy in CT26 Tumor Model
Lourdusamy et al. EPEN-08. MULTI-OMICS PROFILES REVEAL UNIQUE DEFINING MOLECULAR FEATURES OF POSTERIOR FOSSA EPENDYMOMA SUBTYPE A FROM INFANTS
Yılmaz Oncolytic Virotherapy and The Immune System.
HK40102291A (en) Interferon-based cancer treatment method, and pharmaceutical combination
Chang et al. 632. Sustained Function and Enhanced Replicative Capacity of Anti-Tumor CD4+ Effectors by Enforced Co-Stimulation